查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1866549

全球胰島素筆市場－2025-2030年預測

Global Insulin Pens Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球胰島素筆市場預計將從 2025 年的 69.55 億美元成長到 2030 年的 106.56 億美元，複合年成長率為 8.91%。

胰島素筆市場是糖尿病管理的關鍵領域，提供便攜、精準且易於使用的胰島素輸注裝置。這些注射裝置為傳統的管瓶和注射器注射方式提供了一種便捷的替代方案，能夠以最小的浪費輸送精確劑量。全球糖尿病盛行率的上升、胰島素筆設計的技術進步以及不同社會經濟階層的可負擔性是推動市場成長的主要因素。然而，多種胰島素混合使用的限制對市場成長構成了挑戰。

本報告檢驗了胰島素筆市場當前的需求、供應和銷售趨勢，以及影響該市場的最新發展。報告全面分析了關鍵促進因素、限制因素和機遇，並詳細說明了區域產業趨勢、政策和法規，幫助相關人員深入了解法規結構和市場動態。

我們的競爭情報是基於廣泛的二手研究，包括產業協會調查、分析師報告、投資者報告、新聞稿和學術期刊，旨在識別主要企業及其收入貢獻。市場規模採用由下而上和自上而下的方法計算，並經全球胰島素筆價值鏈相關人員的第一手資訊檢驗。我們全面的市場分析整合了各種資訊來源和專有資料集，運用資料三角驗證技術，提供準確的市場區隔和預測。我們透過分析敘述、圖表和圖形呈現洞察，以幫助讀者有效率地理解。預計2024年全球市場規模約75億美元，2030年將達128億美元，複合年成長率為9.3%。主要參與者包括百康（Biocon）、賽諾菲（Sanofi）和諾和諾德（Novo Nordisk）。

主要亮點

  • 糖尿病流行：全球糖尿病患者人數不斷增加（預計到 2024 年將達到 5.5 億），推動了對胰島素筆的需求。
  • 技術創新：筆的設計創新提高了精確度和易用性，推動了筆的廣泛應用。
  • 價格實惠：低價鋼筆提高了各個社會經濟階層的可及性，從而推動了市場成長。
  • 混合限制：無法混合多種胰島素類型限制了其多功能性，阻礙了市場擴張。

成長要素

糖尿病盛行率的不斷上升（預計到2024年全球確診病例將增加6%）顯著推動了胰島素筆作為首選給藥方式的需求。技術進步正在提升用戶的便利性和依從性，例如諾和諾德公司於2024年推出的配備藍牙連接功能的智慧胰島素筆，可用於劑量追蹤。胰島素筆價格的降低也促進了其普及，由於學名藥的競爭，新興市場的價格下降了10%。此外，諸如印度於2024年啟動的5億美元糖尿病照護舉措等支持性醫療政策，也進一步推動了高負擔地區對胰島素筆的採用。

阻礙因素

無法在同一支胰島素筆中混合不同類型的胰島素限制了其多功能性，迫使需要聯合治療的患者使用多種設備。監管壁壘，包括歐盟嚴格的安全標準，增加了製造商的合規成本。開發中國家農村地區認知度低和獲取途徑有限，阻礙了市場滲透。

細分分析

按類型分類：到 2024 年，可重複使用的胰島素筆將佔 60% 的市場佔有率，因其成本效益和永續性而受到青睞，而一次性胰島素筆由於其旅行便利性而穩步成長。

按應用領域分類：1 型糖尿病佔比最大，但由於診斷數量的增加，2 型糖尿病正在迅速成長。

按最終用戶分類：居家醫療（患者自行用藥）是主導，而醫院的使用正在擴大，主要面向住院患者。

區域分析

到2024年，北美將佔據38%的市場佔有率，這主要得益於美國糖尿病高發生率和先進的醫療基礎設施。亞太地區預計將以11.2%的複合年成長率實現最高成長，這主要得益於印度和中國不斷成長的醫療投資和糖尿病病例。歐洲將受益於有利的監管和報銷政策而維持成長。

本報告為業內人士提供關於市場趨勢、監管環境和競爭動態的關鍵洞察。報告重點介紹了智慧胰島素筆的創新技術和新興市場機遇，同時也探討了配藥限制和進入障礙。嚴謹的調查方法，結合一手和二手數據，確保了預測的可靠性，並幫助相關人員理解複雜的市場格局，優先考慮在這一重要的糖尿病管理領域的投資。

本報告的主要優勢：

  • 深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
  • 競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
  • 市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
  • 可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
  • 受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

  • 歷史資料（2022-2024 年）和預測資料（2025-2030 年）
  • 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
  • 競爭對手定位、策略和市場佔有率分析
  • 按業務板塊和地區（國家）分類的收入成長和預測分析
  • 公司概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 分析範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策和法規
  • 策略建議

第4章 技術展望

5. 全球胰島素筆市場（按類型分類）

  • 介紹
  • 一次性胰島素筆
  • 可重複使用的胰島素筆

6. 全球胰島素筆市場（依糖尿病類型分類）

  • 介紹
  • 1型糖尿病
  • 2型糖尿病

7. 全球胰島素筆市場（以最終用戶分類）

  • 介紹
  • 醫院
  • 門診手術中心
  • 居家醫療

8. 全球胰島素筆市場依通路分類

  • 介紹
  • 零售藥房
  • 醫院藥房
  • 網路藥房

9. 全球胰島素筆市場（按地區分類）

  • 介紹
  • 北美洲
    • 按類型
    • 依糖尿病類型
    • 最終用戶
    • 透過分銷管道
    • 按國家/地區
      • 美國
      • 加拿大
      • 墨西哥
  • 南美洲
    • 按類型
    • 依糖尿病類型
    • 最終用戶
    • 透過分銷管道
    • 按國家/地區
      • 巴西
      • 阿根廷
      • 其他
  • 歐洲
    • 按類型
    • 依糖尿病類型
    • 最終用戶
    • 透過分銷管道
    • 按國家/地區
      • 英國
      • 德國
      • 法國
      • 義大利
      • 其他
  • 中東和非洲
    • 按類型
    • 依糖尿病類型
    • 最終用戶
    • 透過分銷管道
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 其他
  • 亞太地區
    • 按類型
    • 依糖尿病類型
    • 最終用戶
    • 透過分銷管道
    • 按國家/地區
      • 日本
      • 中國
      • 印度
      • 韓國
      • 台灣
      • 其他

第10章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 企業合併、協議、商業合作
  • 競爭對手儀錶板

第11章：公司簡介

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Medtronic Plc
  • Insulcloud SL
  • Sanofi SA
  • Diamesco Co., Ltd.
  • Emperra GmbH E-Health Technologies
  • Owen Mumford Ltd
  • Biocon Limited
  • BD
  • B.Braun Melsungen AG
  • Terumo Corporation

第12章 分析方法

簡介目錄
Product Code: KSI061612025

The Global Insulin Pens Market is anticipated to increase from USD 6.955 billion in 2025 to USD 10.656 billion by 2030, at a CAGR of 8.91%.

The insulin pens market is a critical segment of diabetes management, offering portable, accurate, and user-friendly devices for insulin administration. These infusion devices provide a convenient alternative to traditional vial-and-syringe methods, delivering precise doses with minimal wastage. The market is driven by the rising global prevalence of diabetes, technological advancements in pen design, and affordability across diverse socioeconomic groups. However, limitations in mixing multiple insulin types pose challenges to market growth.

This research examines current trends in demand, supply, and sales, alongside recent developments shaping the insulin pens market. It provides a comprehensive analysis of key drivers, restraints, and opportunities, detailing industry trends, policies, and regulations across geographical regions to equip stakeholders with insights into the regulatory framework and market dynamics.

Competitive intelligence identifies major industry players and their revenue contributions, derived from extensive secondary research, including industry association studies, analyst reports, investor presentations, press releases, and journals. Market size for the overall sector and key segments was determined using bottom-up and top-down methodologies, validated with primary inputs from stakeholders in the global insulin pens value chain. Comprehensive market engineering integrated data from diverse sources and proprietary datasets, employing data triangulation for accurate market breakdown and forecasting. Insights are presented through analytical narratives, charts, and graphics for efficient comprehension. The global market was valued at approximately USD 7.5 billion in 2024 and is projected to reach USD 12.8 billion by 2030, growing at a CAGR of 9.3%. Key players profiled include Biocon, Sanofi, and Novo Nordisk, among others.

Key Highlights

  • Diabetes Prevalence: Rising global diabetes cases, reaching 550 million in 2024, drive demand for insulin pens.
  • Technological Advancements: Innovations in pen design enhance accuracy and ease of use, boosting adoption.
  • Affordability: Low-cost pens improve accessibility across socioeconomic groups, fueling market growth.
  • Mixing Limitations: Inability to combine multiple insulin types restricts versatility, hindering market expansion.

Growth Drivers

The increasing prevalence of diabetes, with a 6% rise in diagnoses globally in 2024, significantly boosts demand for insulin pens as a preferred administration method. Technological advancements, such as smart insulin pens with Bluetooth connectivity for dose tracking introduced by Novo Nordisk in 2024, enhance user convenience and compliance. The affordability of insulin pens, with prices dropping by 10% in emerging markets due to generic competition, broadens access. Supportive healthcare policies, such as India's USD 500 million diabetes care initiative in 2024, further drive adoption in high-prevalence regions.

Restraints

The inability to mix different insulin types in a single pen limits versatility, as patients requiring combined therapies must use multiple devices. Regulatory hurdles, including stringent safety standards in the EU, increase compliance costs for manufacturers. Limited awareness and access in rural areas of developing nations restrict market penetration.

Segmentation Analysis

By Type: Reusable insulin pens dominate with a 60% share in 2024, favored for cost-effectiveness and sustainability. Disposable pens grow steadily for convenience in travel.

By Application: Type 1 diabetes accounts for the largest share, while type 2 diabetes sees rapid growth due to rising diagnoses.

By End-User: Homecare settings lead, driven by patient self-administration, with hospitals expanding for inpatient care.

Regional Analysis

North America holds a 38% market share in 2024, driven by high diabetes prevalence and advanced healthcare infrastructure in the U.S. Asia Pacific grows at the highest CAGR of 11.2%, fueled by India and China's healthcare investments and rising diabetes cases. Europe sustains growth through supportive regulations and reimbursement policies.

This report equips industry experts with critical insights into market trends, regulatory landscapes, and competitive dynamics. It highlights opportunities in smart pen innovations and emerging markets while addressing mixing limitations and access barriers. The rigorous methodology, blending primary and secondary data, ensures reliable projections, enabling stakeholders to navigate complexities and prioritize investments in this essential diabetes management sector.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

By Type

  • Disposable Insulin Pens
  • Reusable Insulin Pens

By Diabetes Type

  • Type I Diabetes
  • Type II Diabetes

By End-User

  • Hospitals
  • Ambulatory Surgical Centres
  • Homecare

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL INSULIN PENS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Disposable Insulin Pens
  • 5.3. Reusable Insulin Pens

6. GLOBAL INSULIN PENS MARKET BY DIABETES TYPE

  • 6.1. Introduction
  • 6.2. Type I Diabetes
  • 6.3. Type II Diabetes

7. GLOBAL INSULIN PENS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Ambulatory Surgical Centres
  • 7.4. Homecare

8. GLOBAL INSULIN PENS MARKET BY DISTRIBUTION CHANNEL

  • 8.1. Introduction
  • 8.2. Retail Pharmacies
  • 8.3. Hospital Pharmacies
  • 8.4. Online Pharmacies

9. GLOBAL INSULIN PENS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Type
    • 9.2.2. By Diabetes Type
    • 9.2.3. By End-User
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
      • 9.2.5.1. United States
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. By Type
    • 9.3.2. By Diabetes Type
    • 9.3.3. By End-User
    • 9.3.4. By Distribution Channel
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Others
  • 9.4. Europe
    • 9.4.1. By Type
    • 9.4.2. By Diabetes Type
    • 9.4.3. By End-User
    • 9.4.4. By Distribution Channel
    • 9.4.5. By Country
      • 9.4.5.1. United Kingdom
      • 9.4.5.2. Germany
      • 9.4.5.3. France
      • 9.4.5.4. Italy
      • 9.4.5.5. Others
  • 9.5. Middle East & Africa
    • 9.5.1. By Type
    • 9.5.2. By Diabetes Type
    • 9.5.3. By End-User
    • 9.5.4. By Distribution Channel
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
      • 9.5.5.2. UAE
      • 9.5.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. By Type
    • 9.6.2. By Diabetes Type
    • 9.6.3. By End-User
    • 9.6.4. By Distribution Channel
    • 9.6.5. By Country
      • 9.6.5.1. Japan
      • 9.6.5.2. China
      • 9.6.5.3. India
      • 9.6.5.4. South Korea
      • 9.6.5.5. Taiwan
      • 9.6.5.6. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Novo Nordisk A/S
  • 11.2. Eli Lilly and Company
  • 11.3. Medtronic Plc
  • 11.4. Insulcloud S.L.
  • 11.5. Sanofi S.A.
  • 11.6. Diamesco Co., Ltd.
  • 11.7. Emperra GmbH E-Health Technologies
  • 11.8. Owen Mumford Ltd
  • 11.9. Biocon Limited
  • 11.10. BD
  • 11.11. B.Braun Melsungen AG
  • 11.12. Terumo Corporation

12. RESEARCH METHODOLOGY